Atgam Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to clinical effectiveness in t cell suppression, established role in aplastic anemia, transplant medicine adoption, limited alternative therapies, hospital based immunosuppression protocols.

The growth in the forecast period can be attributed to increasing transplant procedure volumes, growing demand for targeted immunosuppression, expansion of hematology specialty care, improved supportive care frameworks, continued clinical guideline inclusion. Major trends in the forecast period include continued use in aplastic anemia treatment, growing role in transplant rejection management, expansion of immunosuppressive biologic therapies, improved outcomes in hematologic disorders, rising use in specialized transplant centers.

The rising rate of organ transplantations is expected to drive the growth of the atgam market in the coming years. Organ transplantation is a surgical procedure in which a diseased or dysfunctional organ is replaced with a healthy one from a donor. The increase in organ transplants is attributed to factors such as chronic diseases, aging populations, and greater research and funding in transplantation medicine. Atgam (anti-thymocyte globulin) is used in organ transplantation to prevent acute rejection by targeting and depleting T-cells, thereby reducing immune activity. It is often administered alongside other immunosuppressive drugs to improve graft acceptance and clinical outcomes. For instance, in January 2025, according to the Organ Procurement and Transplantation Network, a US-based non-profit scientific and educational organization, the United States recorded 48,149 organ transplants in 2024, surpassing 48,000 and reflecting a 3.3% increase compared to 2023. Of these, 41,119 transplants were from deceased donors, while 7,030 were from living donors. Therefore, the rising rate of organ transplantations is driving the growth of the atgam market.

The growing geriatric population is expected to support the growth of the atgam market going forward. The geriatric population comprises individuals aged 65 and older, who often require specialized healthcare due to age-related vulnerabilities. Advances in medical technology and healthcare have increased life expectancy, leading to a significant rise in the elderly population. Atgam helps prevent organ rejection and manage autoimmune disorders in older adults, who are particularly susceptible to immune-related complications. Modulating the immune system enhances transplant outcomes and improves quality of life for this demographic. For instance, in October 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2030, one in six people worldwide is expected to be aged 60 or older, with the global population of this age group projected to reach 1.4 billion. By 2050, this population is expected to rise to 2.1 billion, effectively doubling current figures, while individuals aged 80 and above are projected to triple, reaching approximately 426 million. Therefore, the increasing geriatric population is driving the growth of the atgam market.

Leading companies in the atgam market are focusing on labeling supplements to maintain regulatory compliance and improve product transparency. Labeling supplements involve submitting updated clinical, safety, or pharmacokinetic data to regulatory authorities to ensure product information reflects the latest evidence. For instance, in February 2023, Pfizer Inc., a US-based multinational pharmaceutical company, submitted a Prior Approval Supplement (PAS) to update the pharmacokinetic (PK) data in the labeling of ATGAM (anti-thymocyte globulin [equine]) sterile solution. ATGAM is indicated for treating renal allograft rejection and moderate to severe aplastic anemia. The supplement included PK data from a study in Japanese adults with aplastic anemia, to be added under the Ethnicity section of the Pharmacokinetics label. The proposed revisions were largely accepted with minor modifications.

Major companies operating in the atgam market are Pfizer Inc.

North America was the largest region in the atgam market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atgam market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atgam market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately affected the atgam market by increasing costs associated with equine serum sourcing and biologic processing equipment. These impacts are most evident in hospital pharmacy procurement and transplant centers. Higher tariffs have placed cost pressure on immunosuppressive treatment protocols. At the same time, tariffs are encouraging localized biologics manufacturing capabilities. This supports long term availability of critical immunosuppressive therapies.

The atgam market research report is one of a series of new reports that provides atgam market statistics, including atgam industry global market size, regional shares, competitors with a atgam market share, detailed atgam market segments, market trends and opportunities, and any further data you may need to thrive in the atgam industry. This atgam market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Atgam is a prescription medication composed of antithymocyte globulin (equine), derived from horse serum, and is designed to suppress the immune system. It is primarily used to treat aplastic anemia and prevent organ transplant rejection by reducing the activity of T lymphocytes, which are key immune cells. Atgam decreases immune system activity, helping prevent attacks on transplanted organs or the body’s own tissues.

The primary clinical indications for Atgam are renal transplant rejection and aplastic anemia. It is an intravenous immunosuppressant administered short-term to prevent acute renal transplant rejection by modulating immune responses. The therapy is distributed through multiple channels, including hospital and retail pharmacies, and is used by adult and geriatric patient populations.

The atgam market consists of sales of the anti-thymocyte globulin (ATG). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.